Document is current
Any future updates will be listed below
-
Authors
Tan, Pedro B. https://orcid.org/0000-0001-9790-9568
Verschoor, Yara L. https://orcid.org/0009-0005-7217-1460
van den Berg, José G.
Balduzzi, Sara https://orcid.org/0000-0003-1205-1895
Kok, Niels F. M.
Ijsselsteijn, Marieke E.
Moore, Kat https://orcid.org/0000-0002-5746-4098
Jurdi, Adham https://orcid.org/0000-0002-2985-3053
Tin, Antony
Kaptein, Paulien https://orcid.org/0000-0002-7784-2818
van Leerdam, Monique E.
Haanen, John B. A. G. https://orcid.org/0000-0001-5884-7704
Voest, Emile E. https://orcid.org/0000-0001-8249-9586
de Miranda, Noel F. C. C. https://orcid.org/0000-0001-6122-1024
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
Wessels, Lodewyk F. A. https://orcid.org/0000-0002-1656-6995
Chalabi, Myriam https://orcid.org/0000-0002-8607-6174
- License Information
-
More Information
Article History
Received: 23 January 2025
Accepted: 24 September 2025
First Online: 20 October 2025
Competing interests
: P.B.T., Y.L.V., J.G.v.d.B., S.B., N.F.M.K., M.E.I., K.M., M.E.v.L., N.F.C.C.d.M. and P.K. declare no competing interests. A.J. and A.T. are employees of Natera, Inc. with stocks and/or stock options to own in the company. A.J. also owns stocks in Iovance, Agenus and Versastem. J.B.A.G.H. is an advisor to Achilles Therapeutics, AstraZeneca, BioNTech, Bristol Myers Squibb, Curevac, Gadeta, Imcyse, Immunocore, Iovance Therapeutics, Ipsen, Merck Serono, Merck Sharp & Dohme, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, PokeAcel, Roche, Sanofi, Sastra Cell Therapy, Third Rock Ventures and T-Knife; has received research grants unrelated to this study from Amgen, Asher Bio, BioNTech US, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis and Sastra Cell Therapy; and owns stock in Neogene Therapeutics. All grants were paid to the institution. E.E.V. reports research funding from Bristol Myers Squibb outside the current work. T.N.S. declares advisory roles for Allogene Therapeutics, Asher Bio, Merus, Neogene Therapeutics and Scenic Biotech; is a stockholder in Allogene Therapeutics, Asher Therapeutics, Cell Control, Merus and Scenic Biotech; and is a venture partner at Third Rock Ventures. L.F.A.W. received project funding from Bristol Myers Squibb outside the current work. M.C. is an advisor to Bristol Myers Squibb, Kineta, Merck Sharp & Dohme, NOUSCOM and Roche/Genentech; and has received research grants unrelated to this study from Bristol Myers Squibb, Agenus, Merck Sharp & Dohme and Roche/Genentech. All grants were paid to the institution.
